US4720385A
(en)
*
|
1983-03-29 |
1988-01-19 |
Miles Laboratories, Inc. |
Protein compositions substantially free from infectious agents
|
US4820805A
(en)
*
|
1983-07-14 |
1989-04-11 |
New York Blood Center, Inc. |
Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
|
US4831012A
(en)
*
|
1984-03-23 |
1989-05-16 |
Baxter International Inc. |
Purified hemoglobin solutions and method for making same
|
US5281579A
(en)
*
|
1984-03-23 |
1994-01-25 |
Baxter International Inc. |
Purified virus-free hemoglobin solutions and method for making same
|
US5185160A
(en)
*
|
1984-06-21 |
1993-02-09 |
Prp, Inc. |
Platelet membrane microvesicles
|
JPS61103836A
(ja)
*
|
1984-10-24 |
1986-05-22 |
Green Cross Corp:The |
フイブロネクチン製剤
|
US4670394A
(en)
*
|
1984-11-16 |
1987-06-02 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C
|
US4613501A
(en)
*
|
1984-12-21 |
1986-09-23 |
New York Blood Center, Inc. |
Inactivation of viruses in labile blood derivatives
|
JPH0825902B2
(ja)
*
|
1985-02-21 |
1996-03-13 |
株式会社ミドリ十字 |
γ−グロブリンの加熱処理方法
|
US4632980A
(en)
*
|
1985-04-03 |
1986-12-30 |
Immunologics |
Ozone decontamination of blood and blood products
|
US4789545A
(en)
*
|
1986-03-31 |
1988-12-06 |
New York Blood Center, Inc. |
Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
|
US4841023A
(en)
*
|
1986-06-25 |
1989-06-20 |
New York Blood Center, Inc. |
Inactivation of viruses in labile protein-containing compositions using fatty acids
|
US4952812A
(en)
*
|
1986-08-26 |
1990-08-28 |
Baxter International Inc. |
Irradiation of blood products
|
FR2603805A1
(fr)
*
|
1986-09-16 |
1988-03-18 |
Transfusion Sanguine Assoc Rgl |
Procede d'inactivation par ozonolyse de micro-organismes contaminants presents dans des materiaux biologiques essentiellement proteiques, les produits obtenus et leurs applications biologiques et analytiques
|
DE3704550A1
(de)
*
|
1987-02-13 |
1988-08-25 |
Behringwerke Ag |
Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
|
CA1339946C
(en)
*
|
1987-03-31 |
1998-07-07 |
Michael J. Griffith |
Ultrapurification process for polypeptides
|
FR2618784B1
(fr)
*
|
1987-07-30 |
1990-04-06 |
Lille Transfusion Sanguine |
Concentre de proteines coagulables par la thrombine, son procede d'obtention et son utilisation a titre de colle biologique
|
DE3730533A1
(de)
*
|
1987-09-11 |
1989-03-30 |
Biotest Pharma Gmbh |
Verfahren zur sterilisation von plasma oder plasmafraktionen
|
DE3733181C1
(de)
*
|
1987-10-01 |
1989-01-19 |
Biotest Pharma Gmbh |
Verfahren zur Herstellung eines hochreinen,virussicheren,biologisch aktiven Transferrinpraeparates
|
DE3877529T2
(de)
*
|
1987-10-23 |
1996-11-07 |
Centre Regional De Transfusion |
Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
|
ATE112287T1
(de)
*
|
1987-12-21 |
1994-10-15 |
Miles Inc |
Faktor viii- gelfiltration.
|
US4909940A
(en)
*
|
1987-12-30 |
1990-03-20 |
New York Blood Center, Inc. |
Extraction of process chemicals from labile biological mixtures with organic alcohols or with halogenated hydrocarbons
|
FR2630115B1
(fr)
*
|
1988-04-14 |
1994-10-28 |
Merieux Inst |
Procede de stabilisation des solutions d'albumine humaine et solution obtenue
|
GB8809177D0
(en)
*
|
1988-04-19 |
1988-05-25 |
Merrell Doe Pharmaceuticals In |
Method of preventing aids transmission-resulting from blood transfusions
|
FR2632309B1
(fr)
*
|
1988-06-07 |
1990-08-24 |
Lille Transfusion Sanguine |
Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus
|
DE3825429C2
(de)
*
|
1988-07-27 |
1994-02-10 |
Biotest Pharma Gmbh |
Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
|
US5094960A
(en)
*
|
1988-10-07 |
1992-03-10 |
New York Blood Center, Inc. |
Removal of process chemicals from labile biological mixtures by hydrophobic interaction chromatography
|
ATE85221T1
(de)
|
1988-11-05 |
1993-02-15 |
Octapharma Ag |
Verfahren zur herstellung eines hochreinen, nicht infektioesen antihaemophiliefaktors mittels chromatographie.
|
JP2926728B2
(ja)
*
|
1988-12-29 |
1999-07-28 |
吉富製薬株式会社 |
蛋白質含有組成物の製造方法
|
JP3005979B2
(ja)
*
|
1989-01-13 |
2000-02-07 |
吉富製薬株式会社 |
蛋白質含有組成物
|
EP0378208B2
(de)
*
|
1989-01-13 |
2003-01-15 |
Mitsubishi Pharma Corporation |
Verfahren zur Herstellung einer Protein enthaltenden Zusammensetzung
|
US5026686A
(en)
*
|
1989-02-01 |
1991-06-25 |
Washington University |
Antiviral peptides
|
JP2852307B2
(ja)
*
|
1989-02-09 |
1999-02-03 |
吉富製薬株式会社 |
ウイルスの除去された蛋白質製剤の製造法
|
US5332578A
(en)
*
|
1989-04-14 |
1994-07-26 |
Prp, Inc. |
Platelet membrane microparticles
|
USH1509H
(en)
*
|
1989-06-09 |
1995-12-05 |
Eran; Harutyun |
Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate
|
CA2034489C
(en)
*
|
1989-06-15 |
1996-07-16 |
Michael E. Hrinda |
Methods for the inactivation of viruses in viral-contaminated pharmaceutical compositions
|
DE4001099A1
(de)
*
|
1990-01-17 |
1991-07-18 |
Octapharma Ag |
Verfahren zur entfernung von viren aus biologischen fluessigkeiten
|
DE4001098A1
(de)
*
|
1990-01-17 |
1991-07-18 |
Octapharma Ag |
Traegergebundene dialkoxyphosphorverbindungen, verfahren zu ihrer herstellung und ihre verwendung
|
US5945098A
(en)
*
|
1990-02-01 |
1999-08-31 |
Baxter International Inc. |
Stable intravenously-administrable immune globulin preparation
|
US5177194A
(en)
*
|
1990-02-01 |
1993-01-05 |
Baxter International, Inc. |
Process for purifying immune serum globulins
|
DE4008852A1
(de)
*
|
1990-03-20 |
1991-09-26 |
Octapharma Ag |
Verfahren zur herstellung von nicht-infektioesem blutplasma
|
US5418130A
(en)
*
|
1990-04-16 |
1995-05-23 |
Cryopharm Corporation |
Method of inactivation of viral and bacterial blood contaminants
|
US6187572B1
(en)
|
1990-04-16 |
2001-02-13 |
Baxter International Inc. |
Method of inactivation of viral and bacterial blood contaminants
|
JP3145696B2
(ja)
*
|
1990-10-05 |
2001-03-12 |
日本ケミカルリサーチ株式会社 |
分泌型免疫グロブリンa製剤の製造法
|
AT395597B
(de)
*
|
1991-01-25 |
1993-01-25 |
Immuno Ag |
Reagens zur bestimmung von faktor viii-aktivitaet
|
US5110910A
(en)
*
|
1991-03-25 |
1992-05-05 |
Miles Inc. |
Virucidal euglobulin precipitation
|
AT402262B
(de)
*
|
1991-06-20 |
1997-03-25 |
Immuno Ag |
Arzneimittel enthaltend aktiviertes protein c
|
AT402891B
(de)
*
|
1991-06-20 |
1997-09-25 |
Immuno Ag |
Verfahren zur herstellung eines inaktivierten blutproduktes
|
DE69227805T2
(de)
*
|
1991-07-05 |
1999-04-29 |
Bayer Ag |
Verwendung von Tri-n-Butylphosphat bei niedrigem pH in Lösungen von biologisch aktiven Proteinen für eine verbesserte viruzide Wirkung
|
DE4125625C2
(de)
*
|
1991-08-02 |
1999-12-02 |
Octapharma Ag Glarus |
Verfahren zur Herstellung von virusinaktivierten Immunglobulinlösungen
|
AT408191B
(de)
*
|
1991-08-19 |
2001-09-25 |
Haemosan Erzeugung Pharmazeuti |
Verfahren zur inaktivierung von prionen
|
DE4142908C2
(de)
*
|
1991-12-24 |
1994-02-10 |
Octapharma Ag Glarus |
Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
|
US5599352A
(en)
*
|
1992-03-19 |
1997-02-04 |
Medtronic, Inc. |
Method of making a drug eluting stent
|
US5510077A
(en)
|
1992-03-19 |
1996-04-23 |
Dinh; Thomas Q. |
Method of making an intraluminal stent
|
US5571166A
(en)
*
|
1992-03-19 |
1996-11-05 |
Medtronic, Inc. |
Method of making an intraluminal stent
|
AT399818B
(de)
*
|
1992-04-24 |
1995-07-25 |
Immuno Ag |
Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
|
JPH06166634A
(ja)
*
|
1992-12-01 |
1994-06-14 |
Green Cross Corp:The |
プラスミノーゲン含有組成物の製造方法
|
US5403834A
(en)
*
|
1992-12-07 |
1995-04-04 |
Eukarion, Inc. |
Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
|
AU6653094A
(en)
*
|
1992-12-16 |
1994-07-04 |
Immuno Aktiengesellschaft |
Process for preparing a virus-safe biological composition
|
AU676011B2
(en)
*
|
1993-02-09 |
1997-02-27 |
Octapharma Ag |
Method for inactivating viruses devoid of lipid envelopes
|
DE4318435C2
(de)
*
|
1993-02-09 |
1997-01-23 |
Octapharma Ag |
Verfahren zur Inaktivierung von Viren, die nicht mit Lipidhüllen versehen sind
|
US20020055710A1
(en)
|
1998-04-30 |
2002-05-09 |
Ronald J. Tuch |
Medical device for delivering a therapeutic agent and method of preparation
|
SE9301582D0
(sv)
*
|
1993-05-07 |
1993-05-07 |
Kabi Pharmacia Ab |
Purification of plasma proteins
|
DE4320294A1
(de)
*
|
1993-06-18 |
1994-12-22 |
Immuno Ag |
Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
|
AU698154B2
(en)
*
|
1993-06-23 |
1998-10-22 |
New York Blood Center, Inc., The |
System for viral inactivation of blood
|
US5744038A
(en)
|
1993-07-30 |
1998-04-28 |
Aruba International Pty Ltd. |
Solvent extraction methods for delipidating plasma
|
DE4325872C1
(de)
*
|
1993-08-02 |
1994-08-04 |
Immuno Ag |
Virusinaktivierte Faktor Xa-Präparation
|
DE4337573C1
(de)
*
|
1993-11-04 |
1995-05-18 |
Octapharma Ag |
Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden
|
DE4342132C1
(de)
*
|
1993-12-10 |
1994-11-03 |
Octapharma Ag |
Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
|
US5486293A
(en)
*
|
1994-03-21 |
1996-01-23 |
Hemasure, Inc. |
Removal of small exogenous molecules from biological fluids
|
US6372716B1
(en)
*
|
1994-04-26 |
2002-04-16 |
Genetics Institute, Inc. |
Formulations for factor IX
|
JPH07308190A
(ja)
*
|
1994-05-18 |
1995-11-28 |
Green Cross Corp:The |
トロンビンの製造方法
|
US6284874B1
(en)
*
|
1994-06-17 |
2001-09-04 |
Alpha Therapeutic Corporation |
Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
|
US5834420A
(en)
*
|
1994-07-14 |
1998-11-10 |
Croix-Rouge De Belgique |
Fibrinogen concentrate obtained from blood plasma, process and plant for its preparation
|
DE4424935C1
(de)
*
|
1994-07-14 |
1996-03-21 |
Immuno Ag |
Humanes virussicheres monomeres Immunglobulin A und Verfahren zu seiner Herstellung
|
DE4431833C1
(de)
*
|
1994-09-07 |
1995-05-18 |
Blutspendedienst Der Drk Lande |
Verfahren zur Herstellung eines AHF-Konzentrates
|
US5506127A
(en)
*
|
1994-09-21 |
1996-04-09 |
Proba; Zbigniew |
Therapeutic grade thrombin produced by chromatography
|
DE4435485C1
(de)
*
|
1994-10-04 |
1996-03-21 |
Immuno Ag |
Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
|
AUPN030794A0
(en)
|
1994-12-22 |
1995-01-27 |
Aruba International Pty Ltd |
Discontinuous plasma or serum delipidation
|
DE19506633A1
(de)
*
|
1995-02-25 |
1996-08-29 |
Octapharma Ag |
Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
|
US6034073A
(en)
*
|
1995-04-24 |
2000-03-07 |
Novavax, Inc. |
Solvent detergent emulsions having antiviral activity
|
FI952196A0
(fi)
*
|
1995-05-08 |
1995-05-08 |
Suomen Punainen Risti Veripalv |
Framstaellning av immunoglobulin
|
DE19528221C2
(de)
*
|
1995-08-01 |
1998-10-22 |
Blutspendedienst Der Drk Lande |
Verfahren zur Herstellung eines virussicheren, therapeutischen Präparates aus Humanplasma
|
US20040053208A1
(en)
*
|
1995-08-29 |
2004-03-18 |
V. I. TECHNOLOGIES, Inc. |
Methods to selectively inactivate parasites in biological compositions
|
US5741894A
(en)
*
|
1995-09-22 |
1998-04-21 |
Baxter International, Inc. |
Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
|
US6686191B1
(en)
*
|
1995-09-22 |
2004-02-03 |
Bayer Healthcare Llc |
Preparation of virally inactivated intravenously injectable immune serum globulin
|
US6005077A
(en)
*
|
1995-11-10 |
1999-12-21 |
Immuno Aktiengesellschaft |
Use of von willebrand factor and pharmaceutical formulation
|
DE19600939C1
(de)
|
1996-01-12 |
1997-08-28 |
Immuno Ag |
Verfahren zur Trennung von IgG und IgA
|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
US6068838A
(en)
*
|
1996-04-29 |
2000-05-30 |
Baxter Aktiengesellschaft |
Purified multimerase
|
US5744586A
(en)
*
|
1996-06-26 |
1998-04-28 |
Alpha Therapeutic Corporation |
Manufacturing process for the production of purified transferrin
|
US5616693A
(en)
*
|
1996-07-01 |
1997-04-01 |
Alpha Therapeutic Corporation |
Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste
|
US5833651A
(en)
*
|
1996-11-08 |
1998-11-10 |
Medtronic, Inc. |
Therapeutic intraluminal stents
|
WO1998030230A1
(fr)
*
|
1997-01-09 |
1998-07-16 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Compositions proteinees et procede de production
|
AT405135B
(de)
*
|
1997-01-17 |
1999-05-25 |
Immuno Ag |
Präparation umfassend thiolgruppen-hältige proteine
|
AT404358B
(de)
|
1997-02-04 |
1998-11-25 |
Immuno Ag |
Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
|
AT406373B
(de)
|
1997-02-27 |
2000-04-25 |
Immuno Ag |
Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
|
TW541179B
(en)
*
|
1997-03-19 |
2003-07-11 |
Green Cross Corp |
Process for preparing immunoglobulin preparation
|
US6126259A
(en)
*
|
1997-03-25 |
2000-10-03 |
Trident International, Inc. |
Method for increasing the throw distance and velocity for an impulse ink jet
|
AT405608B
(de)
*
|
1997-04-08 |
1999-10-25 |
Immuno Ag |
Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
|
AU737566B2
(en)
|
1997-04-08 |
2001-08-23 |
Baxalta GmbH |
An immunotolerant prothrombin complex preparation
|
AT405485B
(de)
|
1997-05-28 |
1999-08-25 |
Immuno Ag |
Eine das vwf-propeptid enthaltende pharmazeutische präparation
|
GB9711927D0
(en)
*
|
1997-06-09 |
1997-08-06 |
Bristol Myers Squibb Co |
Compositions useful as fibrin sealants
|
AT407159B
(de)
†
|
1997-06-13 |
2001-01-25 |
Immuno Ag |
Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
|
US6106454A
(en)
*
|
1997-06-17 |
2000-08-22 |
Medtronic, Inc. |
Medical device for delivering localized radiation
|
US6203536B1
(en)
*
|
1997-06-17 |
2001-03-20 |
Medtronic, Inc. |
Medical device for delivering a therapeutic substance and method therefor
|
US6955917B2
(en)
*
|
1997-06-20 |
2005-10-18 |
Bayer Healthcare Llc |
Chromatographic method for high yield purification and viral inactivation of antibodies
|
US5886154A
(en)
|
1997-06-20 |
1999-03-23 |
Lebing; Wytold R. |
Chromatographic method for high yield purification and viral inactivation of antibodies
|
AT406120B
(de)
|
1997-08-28 |
2000-02-25 |
Immuno Ag |
Gewebekleber
|
AT405739B
(de)
|
1997-09-19 |
1999-11-25 |
Immuno Ag |
Verfahren zur reinigung von antithrombin iii
|
AT407117B
(de)
|
1997-09-19 |
2000-12-27 |
Immuno Ag |
Fibrinschwamm
|
US6015832A
(en)
*
|
1997-12-31 |
2000-01-18 |
The Regents Of The University Of Michigan |
Methods of inactivating bacteria including bacterial spores
|
US6369048B1
(en)
|
1998-01-12 |
2002-04-09 |
V.I. Technologies, Inc. |
Methods and compositions for inactivating viruses
|
US6013099A
(en)
*
|
1998-04-29 |
2000-01-11 |
Medtronic, Inc. |
Medical device for delivering a water-insoluble therapeutic salt or substance
|
US6206914B1
(en)
*
|
1998-04-30 |
2001-03-27 |
Medtronic, Inc. |
Implantable system with drug-eluting cells for on-demand local drug delivery
|
JP4707231B2
(ja)
*
|
1998-06-10 |
2011-06-22 |
スタテンズ セーラム インスティテュート |
マンナン結合レクチンを製造するための精製方法及びmbl医薬品
|
DE60027695T2
(de)
|
1999-02-12 |
2007-04-26 |
Baxter Ag |
Verfahren zur herstellung von fibrinogen und fibronectin sowie proteinzusammesetzungen, welche damit herstellbar sind
|
CN100553678C
(zh)
|
1999-02-22 |
2009-10-28 |
巴克斯特国际有限公司 |
新的无白蛋白的因子ⅷ制剂
|
US6270672B1
(en)
|
1999-08-06 |
2001-08-07 |
Baxter Aktiengesellschaft |
Devices and methods for removing pathogens from biological fluids
|
AT410218B
(de)
|
1999-08-20 |
2003-03-25 |
Baxter Ag |
Verfahren zur herstellung eines qualitätsgesicherten pools biologischer proben
|
US6436344B1
(en)
*
|
1999-11-02 |
2002-08-20 |
American National Red Cross |
Method of inactivating pathogens
|
EP1250929A4
(de)
*
|
1999-12-20 |
2004-12-29 |
Mitsubishi Pharma Corp |
MITTELS PORöSER MEMBRAN BEHANDELTE, VIREN-FREIE PLASMAPROTEIN-VERBINDUNG UND DEREN HERSTELLUNGSPROZESS
|
KR100863823B1
(ko)
*
|
1999-12-22 |
2008-10-15 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
코스미드 dna 작제물 및 이를 제조하고 이용하는 방법
|
AUPQ486699A0
(en)
*
|
1999-12-23 |
2000-02-03 |
Aruba International Pty Ltd |
A method of treating infectious diseases
|
DE10012732A1
(de)
*
|
2000-03-18 |
2001-09-20 |
Aventis Behring Gmbh |
Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
|
IL136552A
(en)
|
2000-06-05 |
2005-05-17 |
Omrix Biopharmaceuticals Ltd |
Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
|
US20020176796A1
(en)
*
|
2000-06-20 |
2002-11-28 |
Purepulse Technologies, Inc. |
Inactivation of microbes in biological fluids
|
US20090017069A1
(en)
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
US7407663B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
US7407662B2
(en)
*
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
US7439052B2
(en)
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
AU2001245240A1
(en)
|
2000-12-14 |
2002-06-24 |
Talecris Biotherapeutics, Inc. |
Method of preparing alpha-1 proteinase inhibitor
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
AU2002318396A1
(en)
*
|
2001-06-21 |
2003-01-08 |
The Cleveland Clinic Foundation |
Homocysteinylated transthyretin
|
US7033500B2
(en)
*
|
2001-06-25 |
2006-04-25 |
Lipid Sciences, Inc. |
Systems and methods using multiple solvents for the removal of lipids from fluids
|
EP1409108A4
(de)
*
|
2001-06-25 |
2007-11-14 |
Lipid Sciences Inc |
Hohlfaserberührungssysteme zur entfernung von lipiden aus fluiden
|
US20030104350A1
(en)
*
|
2001-06-25 |
2003-06-05 |
Bomberger David C. |
Systems and methods using a solvent for the removal of lipids from fluids
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
US20060060520A1
(en)
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
US20030133829A1
(en)
*
|
2001-12-21 |
2003-07-17 |
Baxter Healthcare Corporation |
Process for inactivating pathogens in a biological material
|
CA2496831A1
(en)
*
|
2002-08-26 |
2004-03-04 |
Lipid Sciences, Inc. |
Treating alzheimers using delipidated protein particles
|
US8986607B2
(en)
|
2003-02-27 |
2015-03-24 |
Baxter International Inc. |
Method for the validatable inactivation of pathogens in a biological fluid by irradiation
|
WO2004089402A1
(ja)
*
|
2003-04-09 |
2004-10-21 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
アルブミン製剤の製造方法
|
US20050208083A1
(en)
|
2003-06-04 |
2005-09-22 |
Nanobio Corporation |
Compositions for inactivating pathogenic microorganisms, methods of making the compositons, and methods of use thereof
|
PT1641421T
(pt)
*
|
2003-07-03 |
2019-03-27 |
Hdl Therapeutics Inc |
Métodos e dispositivos para criar derivados de partículas de hdl com conteúdo de lípidos reduzido
|
US7393826B2
(en)
*
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
US20060034943A1
(en)
*
|
2003-10-31 |
2006-02-16 |
Technology Innovations Llc |
Process for treating a biological organism
|
AU2012201036B2
(en)
*
|
2003-12-01 |
2014-12-04 |
Novo Nordisk Health Care Ag |
Virus filtration of liquid factor VII compositions
|
ES2507091T3
(es)
*
|
2003-12-01 |
2014-10-14 |
Novo Nordisk Health Care Ag |
Nanofiltración de soluciones del factor VII para eliminar virus
|
AU2005209303A1
(en)
*
|
2004-01-29 |
2005-08-11 |
Biosynexus, Inc. |
Use of amino-oxy functional groups in the preparation of vaccines conjugates
|
CA2557229C
(en)
|
2004-02-27 |
2012-07-10 |
Octapharma Ag |
A method of providing a purified, virus safe antibody preparation
|
AU2005265960B8
(en)
*
|
2004-06-29 |
2012-01-12 |
Reliance Life Sciences Pvt Ltd |
Process for improvement of virus-safe biological fluids
|
US7993580B2
(en)
*
|
2004-08-24 |
2011-08-09 |
Baxter International Inc. |
Methods for the inactivation of microorganisms in biological fluids, flow through reactors and methods of controlling the light sum dose to effectively inactivate microorganisms in batch reactors
|
GB0423196D0
(en)
|
2004-10-19 |
2004-11-24 |
Nat Blood Authority |
Method
|
AU2005229674B2
(en)
*
|
2004-11-18 |
2010-11-04 |
Kedrion Melville Inc. |
Low concentration solvent/detergent process of immuneglobulin with pre-treatment
|
EP1685852A1
(de)
|
2005-02-01 |
2006-08-02 |
Fondation pour la Recherche Diagnostique |
Set von Einwegbeuteln zur Virusinaktivierung von biologischen Fluids
|
JP2008535918A
(ja)
*
|
2005-04-11 |
2008-09-04 |
ナノバイオ コーポレーション |
感染性の症状を処置するための四級アンモニウムハライド
|
WO2006122476A1
(fr)
*
|
2005-04-29 |
2006-11-23 |
Chengdu Kuachang Medical Industrial Limited |
Procede d’inactivation de virus, systeme de traitement et dispositif correspondants
|
WO2006116899A1
(fr)
*
|
2005-04-29 |
2006-11-09 |
Chengdu Kuachang Medical Industrial Limited |
Système, milieu en phase solide, appareil et méthode pour traitement de bio-liquide
|
FR2887883B1
(fr)
|
2005-06-29 |
2007-08-31 |
Lab Francais Du Fractionnement |
Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines
|
EP1739179A1
(de)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serumfreie stabile Transfektion und Produktion von rekombinanten humanen Proteinen in humanen Zelllinien
|
EP1951200A2
(de)
*
|
2005-08-09 |
2008-08-06 |
Nanobio Corporation |
Eine nanoemulsion enthaltende zusammensetzungen mit entzündungshemmender wirkung
|
US20070128693A1
(en)
*
|
2005-12-06 |
2007-06-07 |
Advantek Serum Laboratories Limited3/F |
Method for the inactivation and removal of dengue virus from biological samples
|
EP1964579A1
(de)
*
|
2007-02-14 |
2008-09-03 |
Fondation pour la Recherche Diagnostique |
Herstellung viral inaktiver biologischer Flüssigkeiten mit hoher Alpha-2-Antiplasmin-Aktivität
|
US8222015B2
(en)
*
|
2007-05-11 |
2012-07-17 |
Toyota Motor Engineering & Manufacturing North America, Inc. |
Heat resistant bioactive composition
|
GB0710321D0
(en)
*
|
2007-05-30 |
2007-07-11 |
Nhs Blood & Transplant |
Method
|
US9956272B2
(en)
|
2007-05-30 |
2018-05-01 |
Bio Products Laboratory Limited |
Methods for preparing factor X, activated factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same
|
EP2077118A1
(de)
|
2008-01-07 |
2009-07-08 |
Gwo Rei Biomedical Technology Corp. |
Gerinnungsfähiges Konzentrat von Plättchenwachstumsfaktoren und Herstellungsverfahren dafür
|
JP2011515170A
(ja)
*
|
2008-03-28 |
2011-05-19 |
リサーチ ファンデーション フォー メディカル デバイシズ |
溶媒/界面活性剤処理による生体液のウイルス不活化方法
|
MX2010013908A
(es)
|
2008-06-24 |
2011-01-21 |
Octapharma Ag |
Procedimiento para purificar factor viii de la coagulacion.
|
JP5779780B2
(ja)
|
2008-11-07 |
2015-09-16 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
第viii因子製剤
|
EP2350271B1
(de)
|
2008-11-20 |
2016-01-27 |
Biogen MA Inc. |
Arginin-inaktivierung von umhüllten viren
|
US20100150942A1
(en)
*
|
2008-12-03 |
2010-06-17 |
Cantor Thomas L |
Affinity purified human polyclonal antibodies and methods of making and using them
|
US8647621B2
(en)
|
2009-07-27 |
2014-02-11 |
Fina Biosolutions, Llc |
Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
|
US8945895B2
(en)
|
2009-07-31 |
2015-02-03 |
Baxter International Inc. |
Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
|
FR2952641B1
(fr)
|
2009-11-18 |
2012-01-13 |
Lfb Biomedicaments |
Procede de traitement du plasma sanguin comprenant une etape de lavage par dispersion
|
CA2836140C
(en)
|
2009-12-17 |
2016-06-21 |
Fina Biosolutions, Llc |
Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
|
AU2011234521B2
(en)
|
2010-03-30 |
2015-04-23 |
Octapharma Ag |
A process for purifying Vitamin K dependent proteins such as coagulation factor IX
|
AU2011234532B2
(en)
|
2010-03-30 |
2015-04-09 |
Octapharma Ag |
Process for the purification of a Growth Factor Protein
|
ES2743156T3
(es)
*
|
2010-04-23 |
2020-02-18 |
Serum Institute Of India Pvt Ltd |
Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
|
EP2399613A1
(de)
|
2010-06-22 |
2011-12-28 |
Research Foundation For Medical Devices |
Plasmafraktionierung mittels Verwendung der Caprylsäure
|
CA2809471A1
(en)
|
2010-09-20 |
2012-03-29 |
Octapharma Ag |
Process for production of fibrinogen
|
CN106928344A
(zh)
|
2010-11-16 |
2017-07-07 |
奥克塔法马股份有限公司 |
用于从含有凝血因子的溶液中减少和/或除去FXI和FXIa的方法
|
WO2012075041A2
(en)
|
2010-11-29 |
2012-06-07 |
New York Blood Center, Inc. |
Method of blood pooling and storage
|
CN103547280B
(zh)
|
2011-04-07 |
2017-06-09 |
艾弗兰纳特有限公司 |
用于药物组合物的巨噬细胞活化因子
|
US20130109807A1
(en)
*
|
2011-10-26 |
2013-05-02 |
Bio-Rad Laboratories, Inc. |
Removal of virucidal agents in mixed mode chromatography
|
US10112972B2
(en)
|
2012-03-13 |
2018-10-30 |
Octapharma Ag |
Process for production of fibrinogen and fibrinogen produced thereby
|
ES2381828B1
(es)
|
2012-03-20 |
2012-11-16 |
Grifols, S.A. |
PROCEDIMIENTO PARA OBTENER UNA COMPOSICION DE IgG MEDIANTE TRATAMIENTO TERMICO
|
US9534029B2
(en)
|
2012-10-03 |
2017-01-03 |
Csl Behring Ag |
Method of purifying proteins
|
SG11201501921SA
(en)
|
2012-10-03 |
2015-04-29 |
Csl Behring Llc |
A method of purifying proteins
|
US20140154233A1
(en)
|
2012-12-05 |
2014-06-05 |
Csl Limited |
Method of purifying therapeutic proteins
|
US10188965B2
(en)
|
2012-12-05 |
2019-01-29 |
Csl Behring Gmbh |
Hydrophobic charge induction chromatographic depletion of a protein from a solution
|
EP3137186B1
(de)
|
2014-04-30 |
2021-01-27 |
Novo Nordisk A/S |
Verfahren zur reinigung von proteinen mithilfe von caprylsäure
|
TR201704471T1
(tr)
*
|
2014-11-05 |
2018-04-24 |
Abbott Gmbh & Co Kg |
Pankreatin İhtiva Eden İyileştirilmiş Güvenlik Profiline Sahip Bileşimlerin Üretilmesi İçin Prosesler Ve Farmasötik Kullanıma Uygun Bileşimler
|
US20200237652A1
(en)
|
2017-08-08 |
2020-07-30 |
Csl Behring Ag |
Hemopexin formulations
|
CN111868232A
(zh)
|
2017-11-22 |
2020-10-30 |
Hdl治疗公司 |
用于对血浆处理系统的流体回路进行灌注的系统和方法
|
CA3087207A1
(en)
|
2017-12-28 |
2019-07-04 |
Hdl Therapeutics, Inc. |
Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
|
EP3945095A1
(de)
|
2020-07-28 |
2022-02-02 |
Bia Separations D.O.O. |
Verfahren zur reinigung von prothrombinkomplexkonzentrat (pcc) und fixierung aus vollständigem plasma oder kryoarmem plasma
|